Merck Licenses Antibiotic From Cubist
Posted on: Friday, 23 March 2007, 15:01 CDT
Merck & Co has licensed lipopeptide antibiotic Cubicin, a treatment for serious infections including MRSA, in Japan from Cubist Pharmaceuticals.
Merck will develop and commercialize Cubicin through its wholly-owned subsidiary, Banyu Pharmaceutical. In exchange for development and commercialization rights in Japan, Merck will pay Cubist $6 million cash upfront.
An additional $39.5 million in total milestone payments could be paid to Cubist for regulatory and sales achievements. Merck will also pay Cubist an undisclosed price for the supply of Cubicin vials to be sold in Japan.
"MRSA is a serious concern in Japan. Cubicin will provide a much needed additional therapy for serious infections, including those caused by MRSA," said Mike Bonney, president and CEO of Cubist.
Source: Datamonitor
Related Articles
- The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use
- Merck Wins Japanese Approval for Colorectal Cancer Drug
- NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
- Astellas/Theravance: FDA Delays Telavancin Approval
- Merck Gets Japan Rights to Cubicin
- Cerexa MRSA Treatment Fast Tracked By FDA
- The Hospital Antibacterial Market Presents New Opportunities for Small Pharmaceutical Companies
- Economic Methodology: Heterogeneity and Relevance
- Research and Markets: LCD Processing: Challenges, Directions, Markets: Japan Dominating the LCD Market
 |
 |
User Comments (0)
RSS Feeds